1. B ASAL I NSULIN AND C ARDIOVASCULAR AND O THER O UTCOMES IN D YSGLYCEMIA T HE ORIGIN T RIAL I NVESTIGATORS NEJM J ULY 26, 2012: 367;4 Charles Wang 4 th Year PharmD Candidate University of Georgia College of Pharmacy 8/27/2012

2. O VERVIEW ORIGIN Trial Outcome Reduction with Initial Glargine Intervention Tested if sufficient basal insulin to normalize fasting plasma glucose levels may reduce cardiovascular events. Funding Sanofi BioPharma Norge Study Dates September 2003 – December 2011

3. B ACKGROUND Diabetes is a chronic metabolic disease in which a person has high blood glucose levels. It involves either the body not producing enough insulin or because the cells do not respond to the insulin that is produced. Globally, as of 2012, an estimated 346 million people have type 2 diabetes. Diabetes has many complications: Cardiovascular disease Ischemic heart disease Stroke Peripheral vascular disease Diabetic retinopathy, nephropathy, and neuropathy

4. B ACKGROUND Elevated blood glucose indicates that there is not enough endogenous insulin to regulate the glucose levels or to overcome underlying insulin resistance Correction of this deficiency may reduce cardiovascular outcomes. United Kingdom Prospective Diabetes Study (UKPDS) 15% reduction in myocardial infarction 13% reduction in death among people with a new- onset type 2 diabetes Normalizing fasting plasma glucose levels may safely reduce incident CV outcomes Exogenous insulin may slow the decline in pancreatic function with time

5. B ACKGROUND Insulin glargine Brand name: Lantus Long acting basal insulin Consists of microcrystals that slowly release insulin Usually given once daily “peakless” profile according to package insert Formulated at an acidic pH of 4 Water soluble at that pH Physiologic pH (~7.4) causes the insulin to come out of solution that forms hexamers Hexamers slows dissociation into insulin monomers which is the physiologically active unit of insulin. Do not mix Lantus with any other insulin Precipitates out of solution and reduces effectiveness

6. D ESIGN Trial tested the effects of titrated basal insulin glargine versus standard of care and of n-3 fatty acid supplements versus placebo on cardiovascular outcomes Study Design Used 2-by-2 factorial design Double-blinded Randomized 537 cardiology, diabetes, or other clinical sites 40 countries

7. D ESIGN Insulin GlargineStandard of Care N-3 fatty-acid supplements Insulin Glargine + N-3 fatty-acid supplements Standard of Care + N-3 fatty-acid supplements PlaceboInsulin Glargine + Placebo Standard of Care + Placebo

8. I NCLUSION C RITERIA Impaired Glucose Tolerance PPG ≥ 140 < 200 mg/dL FPG < 126 mg/dL OR Impaired Fasting Glucose without DM FPG ≥ 110 and < 126 PPG must be <200 mg/dL OR early type 2 diabetes FPG ≥ 126 mg/dL or a PPG ≥ 200 or a previous diagnosis of DM and either: No pharmacologic treatment for at least 10 weeks prior to screening or An A1c of < 150% of the upper limit for the laboratory (<9% if 6%)

9. I NCLUSION C RITERIA OR taking one oral antidiabetic drugs for at least 10 weeks at the time of screening and <8.5% A1c Men or women ≥ 50 years old Must be at risk for cardiovascular disease Prior MI Prior Stroke Prior coronary, carotid, or peripheral arterial revascularization Angina with documented ischemic changes Microalbuminuria or clinical albuminuria A:C ratio > 30 mg/mg LV hypertrophy At least 50% stenosis on angiography of a coronary, carotid, or lower extremity artery Ankle/brachial index <0.9

10. E XCLUSION C RITERIA Type 1 diabetes Requiring insulin treatment Known anti-GAD Ab positivity in the past Autoimmune antibodies differentiates between types of diabetes HgA1c >150% of upper limit (≥9%) CABG within 4 years of screening SrCr > 2.0 mg/dL ALT or AST > 2.5 times upper limit of normal Chronic or recurrent treatment of systemic corticosteroids or niacin treatment Heart Failure of NYHA Class III or IV Prior heart transplant or awaiting heart transplant

11. M ETHODS 12,537 participants 2-by-2 factorial design Follow up for 7 years 6,264 in the Insulin Glargine Group 6,273 in the Standard Care Group In the insulin group, participants added an evening injection to their control regimen and increased the dose at least once weekly Targeting a FPG level of 95 mg/dL Those without a diabetes diagnosis Reduced dose of insulin by 10 units per day and stopped any metformin by the last visit

12. M ETHODS Those in the Standard Care arms were treated on the basis of the investigator’s best judgment and local guidelines Also, those that did not have a diabetes diagnosis and were not using glucose lowering drugs were scheduled for a Glucose Tolerance Test and retested if it did not establish a diagnosis of diabetes.

13. B ASELINE C HARACTERISTICS

17. O UTCOMES Co-primary Outcomes Death from cardiovascular causes, nonfatal myocardial infarction, or nonfatal stroke A revascularization procedure (cardiac, carotid, or peripheral) or hospitalization for heart failure Other outcomes Microvascular events Incident cases of diabetes in participants without baseline diabetes All-cause mortality New or recurrent cancers Hypoglycemic episodes Weight

18. R ESULTS

21. H AZARD R ATIO Used when presenting results with survival analysis data Should not be considered the same as relative risk ratio A hazard is the rate at which events happen Probability=length of time x hazard The hazard ratio is an expression of the hazard or chance of events occurring in the treatment arm as a ratio of the hazard of the events occurring in the control arm Assume proportional hazard Risk does not depend on time A hazard ration of 2 means that the treatment will cause the patient to progress more quickly, that a person that has not progressed has twice the chance of having progressed to a certain point when compared to someone in the control group.

22. R ESULTS Coprimary Outcomes No significant difference in either outcome MI, Stroke, or death from CV causes HR: 1.02; 95%CI 0.94-1.11; P=0.63 Revascularization or Hospitalization for CHF HR: 1.04; 95%CI 0.97-1.11; P=0.27 Other Outcomes All-outcome death HR: 0.98; 95%CI 0.9 to 1.08; P=0.7 Microvascular Events HR: 0.97; 95%CI 0.90 to 1.05; P 0.43

23. R ESULTS 1,456 participants without diabetes at randomization, (737 assigned to Lantus and 719 assigned to standard care) Lantus Group were 28% less likely to develop diabetes OR:0.72; 95%CI, 0.58 to 0.91; P=0.006 No significant difference of incidence of cancer HR: 1.00; 95%CI, 0.88 to 1.13; P=0.97 Incidence of first episode of severe hypoglycemia 1 per 100 person-years in Lantus 0.31 per 100 person years in standard care P=<0.001

24. R ESULTS Weight Changes +1.6 kg in Lantus Group -0.5 kg in standard of care group

25. A UTHOR ’ S C ONCLUSION When used to target normal fasting plasma glucose levels for more than 6 years, insulin glargine had a neutral effect on cardiovascular outcomes and cancers Reduced new-onset diabetes Increased hypoglycemia events Modest increase in weight

26. S TRENGTHS Very large sample size Long follow up duration and high rate of follow- up and treatment adherence 6.2 year average follow up time Well distributed baseline Large and diverse data collection

27. L IMITATIONS Only included relatively controlled diabetics Did not include patients currently on insulin No standard, standard care, thus allowing each physician to determine course of care. Guideline-suggested degrees of glycemic control Did not test more intense versus less intense glucose control

28. D ISCUSSION Metformin was used in 47% of the insulin- glargine group Cardioprotective effect of metformin might have mitigated cardiovascular harm of insulin. 60% of standard care was also on [ Patients that were not diagnosed with diabetes had a reduced incidence of developing diabetes in the Lantus group. Most likely due to the masking of the hyperglycemia by residual Lantus.